Liquidity & Technicals
Liquidity & Technicals
A WW position is a specialist trade, not an institutional core holding: 20-day average daily traded value is roughly $4.5M and a 5-trading-day clip at 20% participation clears only about $4.1M, capping a 5% portfolio position at funds in the $80M-AUM range. The tape is bearish — price is 63% below the 200-day, the most recent 50/200 death cross fired on 2026-03-02, realized 30-day volatility is back near 100%, and short-term RSI/MACD are only just beginning to lift off oversold.
1. Portfolio implementation verdict
5-Day Capacity (20% ADV, $)
Max Fund AUM for a 5% Position ($)
ADV 20d (Traded $)
ADV / Mkt Cap (bp)
Tech Scorecard (−6 to +6)
Illiquid / specialist only. Annual share turnover is roughly 1.4% of float and 20-day traded value sits below 2 basis points of market cap — both well under the institutional implementability threshold. The tape is bearish on every dimension that matters (trend, momentum, relative position in the 52-week range, and a fresh death cross). This name is a workout situation for distressed/event-driven specialists who can absorb 90%+ realized volatility — not a long-only sleeve trade.
2. Price snapshot
Last Close ($)
YTD Return (%)
1y Return (%)
52-Week Position (0–100)
Beta (proxy)
The +2,377% one-year print is an artefact of the May 2025 Chapter 11 reorganisation: pre-petition shares traded as low as $0.13 before old equity was canceled and new equity emerged at roughly $30. The honest read is the YTD number — down 69% on the new equity since 1 January — and the 52-week position of 21, near the lower end of the post-emergence range.
3. Full-history price with 50/200 SMA
Most recent 50/200 death cross: 2026-03-02. It is the third such cross since 2023 and the second since the post-bankruptcy emergence — the prior 2025-06-30 golden cross was an artefact of new-equity issuance, not a genuine accumulation phase.
Price is 63% below the 200-day (current 9.80 vs 200-day 26.30) and 41% below the 50-day. Looking back ten years, the lifetime regimes are visible: a 2017–2018 GLP-1-era spike to $100, a four-year decline as the franchise lost relevance to drug-based weight management, a Chapter 11 reset in mid-2025 at sub-$0.50, and a post-emergence drift lower from $30 toward $10 over nine months. The downtrend that defined 2018–2024 has resumed under the new equity, not reversed.
4. Relative strength
Relative-strength panel skipped. The post-Chapter 11 equity has only nine months of trading history under a new capital structure, and the pre-petition price series is not comparable to today's stock — the share count, debt stack, and economic claim all reset on emergence. Plotting a rebased line vs SPY or XLY across the bankruptcy event would invent a series that doesn't exist for an investor. The only honest cross-asset read: WW is down 69% YTD against an SPY that is mid-single-digits positive, so YTD relative performance is roughly minus 75 percentage points.
5. Momentum panel — RSI + MACD
RSI is 33.7 — recovering off a deeply oversold 22 print on 8 April, and the MACD histogram has just flipped positive (0.26) for the first time since mid-March. The setup is a classic short-term mean-reversion bounce inside an unbroken downtrend. Note the absence of a positive divergence: the April price low of $9.80 was the lowest close since emergence, and RSI also made its lowest reading of the post-emergence period — momentum confirmed the price low rather than diverging from it. That reduces the probability that this is the start of a durable bottom.
6. Volume, volatility, sponsorship
Average daily volume has declined, not built, in the four months since the price began rolling over: 50-day average peaked near 330k shares in mid-November and has drifted to 290–320k since. Spikes are concentrated on selling days (such as 17 March's 915k-share day, when price gapped to a fresh post-emergence low). There is no evidence of institutional accumulation — the higher-volume days have been distribution.
The 5-year window (chart capped at 200% for readability — June–August 2025 readings during the bankruptcy and reorganisation event reached roughly 1,275%) shows that WW has rarely traded as a normal-vol stock. Realized 30-day vol of 99% sits near the 80th-percentile band of its own 10-year history and roughly 4–5x the broad market. The vol regime is "stressed" and has been for most of the past two years — sponsorship has been event-driven (restructuring funds, retail squeeze flows) rather than fundamental.
7. Institutional liquidity panel
WW is not institutionally implementable under normal participation limits. The thin-trading flags are absolute: 20-day traded value sits below 2 basis points of market cap, and annualised share turnover is around 1.4% of the float. The capacity numbers below are for fund-AUM sizing only — they should not be read as a green light to build a meaningful position.
A. ADV & turnover
ADV 20d (Shares)
ADV 20d (Traded $)
ADV 60d (Shares)
ADV / Mkt Cap (bp)
Annual Turnover (%)
B. Fund-capacity table
The reverse calculation: given a five-day position-build budget at a given participation rate, what is the largest fund AUM that can take a 2%, 5%, or 10% position?
A 5%-of-portfolio position is implementable in five trading days only for funds up to roughly $81M AUM at 20% ADV participation, or $41M at the more conservative 10% rate. A $1B fund hitting a 1% target position would need roughly six trading weeks at 20% participation just to enter — and a comparable window to exit, doubling a round-trip implementation cost that is already high in volatility terms.
C. Liquidation runway
Issuer-level position-sizing table omitted. Total shares outstanding in the underlying file appears to be parsed at the wrong unit, so any "X% of market cap → days to exit" table built off it would be meaningless at the issuer level. The fund-AUM table above is independent of market cap and is the operative implementability number.
D. Execution friction
The 60-day median daily range — the proxy for intraday impact and quoted-spread cost — is 3.3% of price. That is well above the 2% level at which large-order impact starts to compound meaningfully and reflects the post-emergence float still being priced. A 100k-share order is roughly a quarter of a normal day's volume; expect to pay tape-impact cost on top of the spread for any block above that size.
Bottom line: the largest issuer position that clears the 5-day threshold at 20% ADV is effectively zero of float in the institutionally-sized sense — even a $20M build is two business weeks of full participation. At 10% ADV that doubles. This is a name to trade in scaled-out tranches over multiple weeks, or not at all.
8. Technical scorecard + stance
Stance — bearish on a 3-to-6-month horizon. The tape is in a confirmed downtrend, the most recent 50/200 cross fired bearish, momentum is only just starting to stabilise from oversold, and there is no volume signature of institutional accumulation. The two specific levels that would change the read:
- Reclaim of the 50-day SMA at $16.59 on rising volume — that would void the death cross, put price within striking distance of the 200-day, and flip the momentum scorecard from −3 to neutral. Without it, every rally is sellable.
- Breach of the post-emergence intraday low near $8.50 on heavy volume — that would confirm the new-equity reset has failed to mark a durable floor and open the path to single digits below the post-emergence range.
Liquidity is the binding constraint, not the view. Even for a fund that wanted to take the contrarian-distressed side here, the position would have to be built over multiple weeks at a sub-$80M-AUM fund size for any meaningful weight, and exited under the same constraint into what is currently a low-sponsorship tape. The correct action for institutional readers is avoid or watchlist-only — there is no way to express a thesis here at portfolio-relevant size without becoming the marginal price-setter, and the technical setup gives no incremental reason to take that risk today.